Horizon Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HORIZON
HORIZON has nine approved drugs.
There are fifty-two US patents protecting HORIZON drugs.
Summary for Horizon
| US Patents: | 52 |
| Tradenames: | 7 |
| Ingredients: | 7 |
| NDAs: | 9 |
| Patent Litigation for Horizon: | See patent lawsuits for Horizon |
| PTAB Cases with Horizon as patent owner: | See PTAB cases with Horizon as patent owner |
Drugs and US Patents for Horizon
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Horizon Therap Us | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | AA | RX | Yes | Yes | 10,183,006 | ⤷ Start Trial | ⤷ Start Trial | |||
| Horizon | PROCYSBI | cysteamine bitartrate | GRANULE, DELAYED RELEASE;ORAL | 213491-001 | Feb 14, 2020 | RX | Yes | No | 9,192,590*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Horizon | PROCYSBI | cysteamine bitartrate | GRANULE, DELAYED RELEASE;ORAL | 213491-001 | Feb 14, 2020 | RX | Yes | No | 9,233,077*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-003 | Jul 26, 2012 | DISCN | Yes | No | 9,504,699 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Horizon | PENNSAID | diclofenac sodium | SOLUTION;TOPICAL | 204623-001 | Jan 16, 2014 | DISCN | Yes | No | 8,741,956 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Horizon Therap Us | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | AA | RX | Yes | Yes | 10,183,005 | ⤷ Start Trial | ⤷ Start Trial | |||
| Horizon | PENNSAID | diclofenac sodium | SOLUTION;TOPICAL | 204623-001 | Jan 16, 2014 | DISCN | Yes | No | 9,539,335 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Horizon
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-002 | Jul 26, 2012 | 8,309,124 | ⤷ Start Trial |
| Horizon | DUEXIS | famotidine; ibuprofen | TABLET;ORAL | 022519-001 | Apr 23, 2011 | 8,501,228 | ⤷ Start Trial |
| Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | 8,557,285 | ⤷ Start Trial |
| Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | 7,745,466 | ⤷ Start Trial |
| Horizon | DUEXIS | famotidine; ibuprofen | TABLET;ORAL | 022519-001 | Apr 23, 2011 | 8,067,451 | ⤷ Start Trial |
| Horizon | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-001 | Jul 26, 2012 | 9,040,085 | ⤷ Start Trial |
| Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | 8,852,636 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HORIZON drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 1 mg, 2 mg, and 5 mg | ➤ Subscribe | 2012-11-26 |
| ➤ Subscribe | Tablets | 800 mg/26.6 mg | ➤ Subscribe | 2011-12-06 |
| ➤ Subscribe | Topical Solution | 2.0% | ➤ Subscribe | 2014-06-03 |
| ➤ Subscribe | Delayed-release Tablet | 375 mg/20 mg and 500 mg/20 mg | ➤ Subscribe | 2010-11-05 |
| ➤ Subscribe | Oral Liquid | 1.1 g/mL | ➤ Subscribe | 2013-11-19 |
| ➤ Subscribe | Topical Solution | 1.5% | ➤ Subscribe | 2012-07-11 |
International Patents for Horizon Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovenia | 2760479 | ⤷ Start Trial |
| Croatia | P20181877 | ⤷ Start Trial |
| Mexico | 2014003854 | ⤷ Start Trial |
| Australia | 2007311019 | ⤷ Start Trial |
| Philippines | 12015502783 | ⤷ Start Trial |
| Portugal | 2846791 | ⤷ Start Trial |
| Brazil | PI0707277 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Horizon Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3141251 | 301099 | Netherlands | ⤷ Start Trial | PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016 |
| 2203431 | 92666 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119 |
| 0984957 | 2012/048 | Ireland | ⤷ Start Trial | PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812 |
| 1919458 | SPC/GB14/019 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: CYSTEAMINE; REGISTERED: UK EU/1/13/861 20130910 |
| 2330892 | 1690060-7 | Sweden | ⤷ Start Trial | PRODUCT NAME: GLYCEROL PHENYLBUTYRATE; REG. NO/DATE: EU/1/15/1062 20151201 |
| 2330892 | 635 | Finland | ⤷ Start Trial | |
| 2822954 | LUC00083 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/18/1289 20180625 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
